News
🇪🇺 EuropeLatest pharmaceutical news, drug approvals, and EMA regulatory updates
Latest News
GRIN Therapeutics Expands Phase 3 Beeline Study for Radiprodil to Europe for GRIN-NDD Treatment
GRIN Therapeutics initiates Phase 3 Beeline study in Europe for investigational radiprodil targeting GRIN-NDD, expanding global clinical program.
FDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Receives Key Diabetes Drug Approval
FDA approves LANGLARA (insulin glargine-aldy) as interchangeable biosimilar to Lantus for diabetes treatment in adults and pediatric patients.
Vertex CASGEVY Gene Therapy Reaches 60,000+ Eligible Patients Across 10 Countries as Q1 2026 Results Show Global Expansion
Vertex's CASGEVY, the first approved CRISPR gene therapy, now serves 60,000+ eligible sickle cell disease and beta thalassemia patients across 10 countries.
Oncolytics Biotech Pelareorep Shows Durable Responses in RAS-Mutant Colorectal Cancer Trial
Oncolytics Biotech reports sustained clinical benefit with pelareorep immunotherapy in second-line RAS-mutant MSS colorectal cancer patients.
Nuvation Bio's IBTROZI Generates $18.5M Revenue in Q1 2026, Shows Strong First-Line Adoption in ROS1+ NSCLC
Nuvation Bio reports $18.5M Q1 2026 revenue for IBTROZI (taletrectinib) with majority of 200 new patients being TKI-naïve ROS1+ NSCLC cases.
Swiss Biotech Day: Key Takeaways and Highlights
Swiss Biotech Day convenes pharmaceutical innovators and investors to discuss emerging trends in drug development, regulatory strategy, and collaborative opportunities shaping Europe's biotech landscape. Key themes include precision medicine adoption, AI-driven discovery, and sustained challenges in venture capital access.
FDA Approves Auvelity for MDD: Axsome Therapeutics Scores Win
The U.S. Food and Drug Administration (FDA) has approved Auvelity, a novel oral antidepressant developed by Axsome Therapeutics, for the treatment of Major Depressive Disorder (MDD) in adults. This approval represents a significant advancement in the mental health landscape.
Purdue Pharma Shutdown: $7.4B Deal Ends OxyContin Maker's Operations
Purdue Pharma, the manufacturer of OxyContin, is ceasing operations following a $7.4 billion settlement agreement. This landmark deal aims to address the company's role in the opioid crisis and provide compensation to victims.
EULAR 2026: Immutep's IMP761 Phase I Data Preview
Immutep will present Phase I clinical trial data for its investigational drug IMP761 at the EULAR 2026 Congress. IMP761, a first-in-class LAG-3 agonist antibody, is being developed for the treatment of autoimmune diseases.
Novelty Nobility Expands AGC Biologics Partnership for Bispecific Antibody Manufacturing
South Korean biotech Novelty Nobility expands manufacturing deal with AGC Biologics to advance bispecific antibody candidate through GMP production in Japan.
Smartee Denti-Technology Advances Mandibular Repositioning Technology at European Aligner Society Congress 2026
Smartee Denti-Technology presents breakthrough mandibular repositioning innovations and European expansion strategy at EAS Congress 2026 in Brussels.
Swiss Biotech Day 2026: AI, Oncology, Microbiome Highlights
Swiss Biotech Day 2026 in Basel highlights AI in drug discovery, precision oncology, and microbiome therapies, featuring presentations from Evotec, Nvidia, and Ferring Pharmaceuticals.
Purdue Pharma Dissolution Approved: What It Means for Opioid Crisis
Purdue Pharma, the maker of OxyContin, is set to dissolve after a judge approved its criminal sentence. This landmark decision is a significant development in the ongoing legal battles surrounding the opioid crisis.
Auvelity FDA Approval: New Hope for MDD Patients
The FDA has approved Auvelity, a groundbreaking oral antidepressant from Axsome Therapeutics, marking a significant advancement in treating major depressive disorder (MDD). This approval introduces a novel mechanism of action for patients seeking effective relief.
FDA Approves Auvelity for MDD: Axsome Therapeutics' New Antidepressant
The FDA has granted approval for Auvelity, a new oral antidepressant developed by Axsome Therapeutics, to treat major depressive disorder (MDD) in adults. This marks a significant advancement in mental health treatment, offering a novel mechanism of action and potentially rapid symptom relief.
SynbioTech Unveils Microbiome-Based Platform for Women's Healthy Aging at Vitafoods Europe 2026
Taiwan-based SynbioTech presents clinical evidence for probiotic solutions targeting women's muscle maintenance, gut health, and metabolic balance at Vitafoods.
Curaleaf Appoints Torsten Greif to Board as European Medical Cannabis Market Expands
Curaleaf Holdings appoints Torsten Greif to its board of directors to strengthen European medical cannabis operations and EU-GMP certified product distribution.
Pharmaceutical Manufacturing Software Market to Reach $7.87 Billion by 2030, Driven by 15.8% CAGR Growth
Pharmaceutical manufacturing software market grows from $3.82B to $4.43B in 2026 with 15.8% CAGR, projected to reach $7.87B by 2030 amid regulatory demands.
GoodRx Offers Ozempic Pill Access for Type 2 Diabetes Patients at $149 Monthly
GoodRx now provides self-pay access to Novo Nordisk's oral Ozempic for type 2 diabetes patients starting at $149/month nationwide.
Plozasiran TGA Approval in Australia for FCS Patients
Arrowhead Pharmaceuticals has announced the Therapeutic Goods Administration (TGA) approval of REDEMPLO® (plozasiran) in Australia for patients with Familial Chylomicronemia Syndrome (FCS). This landmark decision broadens global access to a crucial treatment for this rare genetic disorder.